4.6 Article

High Yields of Oligodendrocyte Lineage Cells from Human Embryonic Stem Cells at Physiological Oxygen Tensions for Evaluation of Translational Biology

Journal

STEM CELL REPORTS
Volume 1, Issue 5, Pages 437-450

Publisher

CELL PRESS
DOI: 10.1016/j.stemcr.2013.09.006

Keywords

-

Funding

  1. Multiple Sclerosis Society UK
  2. Evelyn Trust
  3. Medical Research Council
  4. Wellcome Trust
  5. National Institute for Health Research (Cambridge Biomedical Research Centre)
  6. Sir David Walker Fellowship
  7. joint Medical Research Council
  8. Multiple Sclerosis Society Clinical Research Training Fellowship [G0800487]
  9. Raymond and Beverly Sackler Studentship
  10. MRC [G0800487] Funding Source: UKRI
  11. Medical Research Council [G0800487] Funding Source: researchfish
  12. National Institute for Health Research [NF-SI-0508-10335] Funding Source: researchfish
  13. Rosetrees Trust [M144] Funding Source: researchfish

Ask authors/readers for more resources

We have established and efficient system to specify NG2/PDGF-R alpha/OLIG2+ oligodendrocyte precursor cells (OPCs) from human embryonic stem cells (hESCs) at low, physiological (3%) oxygen levels. This was achieved via both forebrain and spinal cord origins, with up to 98% of cells expressing NG2. Developmental insights reveal a critical role for fibroblast growth factor 2 (FGF-2) in OLIG2 induction via ventral forebrain pathways. The OPCs mature in vitro to express O4 (46%) and subsequently become galactocerebroside (GALC), O1, and myelin basic protein-positive (MBP+) multibranching oligodendrocytes. These were cultured alongside hESC-derived neurons. The electrophysiological properties of human OPCs are similar to those of rat OPCs, with large voltage-gated sodium currents and the ability to fire action potentials. Exposure to a selective retinoid X receptor agonist increased the proportion of O4+ oligodendrocytes that express MBP from 5% to 30%. Thus, we have established a developmentally engineered system to investigate the biological properties of human OPCs and test the effects of putative remyelinating agents prior to clinical application.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available